Kirwin Patrick D.

Director Kirwin Patrick D. buys 4,000 shares of PMN at $11.33 on 2026-04-22; position up 612.6% post-transaction. Stock now -61.1% from 52-week high.

Kirwin Patrick D., a director at ProMIS Neurosciences, purchased 4,000 shares at $11.33 on 2026-04-22, increasing his holding by 612.6% and committing $45,320.00 to the position. This marks his second insider buy in the company's equity; his first open-market purchase at PMN on 2024-08-14 achieved a 90d return of +1861.3%, well-timed on both 30-day (+2361.6%) and 90-day bases. The current share price of $10.88 sits -61.1% below the 52-week high of $28.00 and -37.6% over the trailing 30 days, suggesting the director is purchasing into a sharp recent decline after the stock had risen 15.4% over the prior 90 days. The company reported a full-year net loss of $-11,580,126.00 on a $97,568,499.84 market capitalization, indicating unprofitability. This substantial position increase by a director during a downtrend, paired with his prior success timing a buy at this ticker, merits investor attention to the company's near-term fundamentals and the director's forward view.

Director Kirwin purchased 10,000 shares of PMN at $1.25; stock down 55.5% from 52-week high despite unprofitable $-2.6M FY.

Director Patrick D. Kirwin purchased 10,000 shares at $1.25 on 2024-08-14, increasing his stake by 18.9% to 62,983 shares post-transaction. The purchase occurred as PMN stock traded down 55.5% from its 52-week high of $70.25 and down 41.8% over the prior 30 days, amid a backdrop of negative full-year net income of $-2.6M. The transaction represents a discrete insider acquisition during a period of significant price weakness and financial underperformance, warranting investor attention to whether this signals management confidence in a recovery or reflects structural challenges at the company.